Biogen Statistics
Total Valuation
Biogen has a market cap or net worth of $22.63 billion. The enterprise value is $25.26 billion.
| Market Cap | 22.63B |
| Enterprise Value | 25.26B |
Important Dates
The last earnings date was Thursday, October 30, 2025, before market open.
| Earnings Date | Oct 30, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Biogen has 146.70 million shares outstanding. The number of shares has increased by 0.36% in one year.
| Current Share Class | 146.70M |
| Shares Outstanding | 146.70M |
| Shares Change (YoY) | +0.36% |
| Shares Change (QoQ) | +0.27% |
| Owned by Insiders (%) | 0.17% |
| Owned by Institutions (%) | 89.92% |
| Float | 146.23M |
Valuation Ratios
The trailing PE ratio is 14.06 and the forward PE ratio is 11.30. Biogen's PEG ratio is 12.15.
| PE Ratio | 14.06 |
| Forward PE | 11.30 |
| PS Ratio | 2.17 |
| Forward PS | 2.40 |
| PB Ratio | 1.21 |
| P/TBV Ratio | 9.49 |
| P/FCF Ratio | 9.82 |
| P/OCF Ratio | 9.22 |
| PEG Ratio | 12.15 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.41, with an EV/FCF ratio of 10.96.
| EV / Earnings | 15.70 |
| EV / Sales | 2.51 |
| EV / EBITDA | 7.41 |
| EV / EBIT | 9.55 |
| EV / FCF | 10.96 |
Financial Position
The company has a current ratio of 2.72, with a Debt / Equity ratio of 0.36.
| Current Ratio | 2.72 |
| Quick Ratio | 1.77 |
| Debt / Equity | 0.36 |
| Debt / EBITDA | 1.87 |
| Debt / FCF | 2.86 |
| Interest Coverage | 10.18 |
Financial Efficiency
Return on equity (ROE) is 9.31% and return on invested capital (ROIC) is 6.92%.
| Return on Equity (ROE) | 9.31% |
| Return on Assets (ROA) | 5.75% |
| Return on Invested Capital (ROIC) | 6.92% |
| Return on Capital Employed (ROCE) | 10.21% |
| Revenue Per Employee | $1.32M |
| Profits Per Employee | $211,506 |
| Employee Count | 7,605 |
| Asset Turnover | 0.35 |
| Inventory Turnover | 1.01 |
Taxes
In the past 12 months, Biogen has paid $295.50 million in taxes.
| Income Tax | 295.50M |
| Effective Tax Rate | 15.52% |
Stock Price Statistics
The stock price has decreased by -14.85% in the last 52 weeks. The beta is 0.14, so Biogen's price volatility has been lower than the market average.
| Beta (5Y) | 0.14 |
| 52-Week Price Change | -14.85% |
| 50-Day Moving Average | 144.35 |
| 200-Day Moving Average | 135.22 |
| Relative Strength Index (RSI) | 63.42 |
| Average Volume (20 Days) | 1,526,362 |
Short Selling Information
The latest short interest is 5.19 million, so 3.54% of the outstanding shares have been sold short.
| Short Interest | 5.19M |
| Short Previous Month | 4.88M |
| Short % of Shares Out | 3.54% |
| Short % of Float | 3.55% |
| Short Ratio (days to cover) | 2.91 |
Income Statement
In the last 12 months, Biogen had revenue of $10.07 billion and earned $1.61 billion in profits. Earnings per share was $10.97.
| Revenue | 10.07B |
| Gross Profit | 7.71B |
| Operating Income | 2.65B |
| Pretax Income | 1.90B |
| Net Income | 1.61B |
| EBITDA | 3.41B |
| EBIT | 2.65B |
| Earnings Per Share (EPS) | $10.97 |
Balance Sheet
The company has $3.96 billion in cash and $6.59 billion in debt, giving a net cash position of -$2.63 billion or -$17.93 per share.
| Cash & Cash Equivalents | 3.96B |
| Total Debt | 6.59B |
| Net Cash | -2.63B |
| Net Cash Per Share | -$17.93 |
| Equity (Book Value) | 18.21B |
| Book Value Per Share | 124.11 |
| Working Capital | 5.65B |
Cash Flow
In the last 12 months, operating cash flow was $2.45 billion and capital expenditures -$149.20 million, giving a free cash flow of $2.30 billion.
| Operating Cash Flow | 2.45B |
| Capital Expenditures | -149.20M |
| Free Cash Flow | 2.30B |
| FCF Per Share | $15.71 |
Margins
Gross margin is 76.56%, with operating and profit margins of 26.28% and 15.98%.
| Gross Margin | 76.56% |
| Operating Margin | 26.28% |
| Pretax Margin | 18.92% |
| Profit Margin | 15.98% |
| EBITDA Margin | 33.87% |
| EBIT Margin | 26.28% |
| FCF Margin | 22.89% |
Dividends & Yields
Biogen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.36% |
| Shareholder Yield | -0.36% |
| Earnings Yield | 7.11% |
| FCF Yield | 10.18% |
Analyst Forecast
The average price target for Biogen is $174.11, which is 12.86% higher than the current price. The consensus rating is "Buy".
| Price Target | $174.11 |
| Price Target Difference | 12.86% |
| Analyst Consensus | Buy |
| Analyst Count | 22 |
| Revenue Growth Forecast (5Y) | -0.13% |
| EPS Growth Forecast (5Y) | 9.30% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on January 18, 2001. It was a forward split with a ratio of 3:1.
| Last Split Date | Jan 18, 2001 |
| Split Type | Forward |
| Split Ratio | 3:1 |
Scores
Biogen has an Altman Z-Score of 3 and a Piotroski F-Score of 6.
| Altman Z-Score | 3 |
| Piotroski F-Score | 6 |